Wedbush Securities Inc. Grows Stock Position in Zoetis Inc. $ZTS

Wedbush Securities Inc. raised its position in Zoetis Inc. (NYSE:ZTS) by 12.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,167 shares of the company’s stock after buying an additional 994 shares during the quarter. Wedbush Securities Inc.’s holdings in Zoetis were worth $1,430,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Savvy Advisors Inc. raised its holdings in shares of Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock worth $67,000 after purchasing an additional 152 shares during the last quarter. Canoe Financial LP raised its stake in Zoetis by 859.0% in the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after purchasing an additional 11,975 shares in the last quarter. Strs Ohio purchased a new stake in Zoetis in the first quarter valued at approximately $22,891,000. Finally, Soros Capital Management LLC lifted its position in Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after purchasing an additional 4,230 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.5%

Shares of NYSE:ZTS opened at $120.20 on Monday. The stock has a market capitalization of $52.97 billion, a P/E ratio of 20.69, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The stock’s 50-day moving average price is $144.21 and its 200-day moving average price is $152.63. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $117.26 and a 12-month high of $181.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the business posted $1.58 EPS. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. lowered their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. UBS Group dropped their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Finally, Stifel Nicolaus set a $140.00 price objective on Zoetis in a research report on Tuesday, November 4th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.